U.S. FOOD & DRUG ADMINISTRATION

Our STN: BL 125652/25

SUPPLEMENT APPROVAL
June 15, 2022

Grifols Diagnostic Solutions, Inc.
Attention: Amanda Doe
10804 Willow Court
San Diego, CA 92127

Dear Amanda Doe:

We have approved your request received April 25, 2022, to supplement your Biologics License Application (BLA) under section 351(a) of the Public Health Service Act for Procleix Ultrio Elite Assay to provide an updated version of the package insert (Rev 007) with the correct cadaveric specimen storage temperature figure within the Specimen Collection, Storage and Handling Section.

We hereby approve the draft package insert labeling submitted with the submission, received on April 25, 2022. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website at http://www.fda.gov/udi.

Please submit all final printed labeling as PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

The CBER Document Control Center (DCC) will process paper and electronic media (CD/DVD, USB drive, etc.) submissions sent via U.S. mail or courier **effective immediately.**

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address, unless otherwise specified:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

We will include the information contained in the above-referenced supplement in your BLA file.

Sincerely,

Hira L. Nakhasi, PhD
Director
Division of Emerging and
Transfusion Transmitted Diseases
Office of Blood Research and Review
Center for Biologics Evaluation and Research